A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission-Reference-Cited by-同舟云学术

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission

Published:2016-01 Issue:1 Volume:2 Page:e000133
ISSN:2056-5933
Container-title:RMD Open
language:en
Short-container-title:RMD Open

Author:

Chatzidionysiou Katerina,Turesson Carl,Teleman Annika,Knight Ann,Lindqvist Elisabet,Larsson Per,Cöster Lars,Forslind Kristina,van Vollenhoven Ronald,Heimbürger Mikael

Publisher

BMJ

Subject

Immunology,Immunology and Allergy,Rheumatology

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-07-25

2. Disease activity–guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study;Rheumatology;2024-02-12

3. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission;Arthritis & Rheumatology;2024-01-25

4. Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review;Arthritis Research & Therapy;2023-11-20

5. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial;Annals of the Rheumatic Diseases;2023-08-22